Sanara MedTech Inc. Common Stock (SMTI)

Price$21.92

Value ScoreD

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)3.14%

Price vs S&P 500 (4W)10.54%

VGM Score50.18

Market Capitalization$208.85M

All Metrics

P/CF (Annual)30.77x

Book Value / Share (Quarterly)$0.77

P/TBV (Annual)36.61x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)31.03%

Cash Flow / Share (Quarterly)$0.37

Price vs S&P 500 (YTD)-13.33%

Gross Margin (TTM)93.06%

Net Profit Margin (TTM)-38.64%

EPS (TTM)$-3.88

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-3.88

Revenue Growth (5Y)45.91%

EPS (Annual)$-4.36

ROI (Annual)-72.36%

Gross Margin (Annual)92.71%

Net Profit Margin (5Y Avg)-20.87%

Cash / Share (Quarterly)$1.48

Revenue Growth QoQ (YoY)18.62%

ROA (Last FY)-51.50%

Revenue Growth TTM (YoY)-10.80%

EBITD / Share (TTM)$1.11

ROE (5Y Avg)-142.30%

Operating Margin (TTM)8.13%

Cash Flow / Share (Annual)$0.24

P/B Ratio29.71x

P/B Ratio (Quarterly)22.41x

Net Income / Employee (Annual)$-347,800

EV / Revenue (TTM)2.96x

Net Interest Coverage (TTM)0.95x

ROA (TTM)-43.04%

EV / EBITDA (TTM)25.19x

EPS Incl Extra (Annual)$-4.36

Current Ratio (Annual)1.80x

Quick Ratio (Quarterly)1.99x

3-Month Avg Trading Volume0.06M

52-Week Price Return-22.25%

EV / Free Cash Flow (Annual)112.97x

Revenue / Employee (TTM)$756,300

Tangible BV / Share (Quarterly)$1.30

P/S Ratio (Annual)2.03x

Asset Turnover (Annual)1.41x

52-Week High$35.95

Operating Margin (5Y Avg)-11.50%

EPS Excl Extra (Annual)$-4.36

CapEx CAGR (5Y)23.17%

26-Week Price Return19.07%

Quick Ratio (Annual)1.54x

13-Week Price Return8.16%

Total Debt / Equity (Annual)7.74x

Current Ratio (Quarterly)2.28x

Enterprise Value$241.48M

Revenue / Share Growth (5Y)34.46%

Asset Turnover (TTM)1.15x

Book Value / Share Growth (5Y)-7.43%

Revenue / Employee (Annual)$954,800

Inventory Turnover (Annual)2.24x

Pretax Margin (Annual)-0.38%

Cash / Share (Annual)$1.85

3-Month Return Std Dev64.32%

Gross Margin (5Y Avg)89.56%

Net Income / Employee (TTM)$-310,900

ROE (Last FY)-632.53%

Net Interest Coverage (Annual)0.78x

EPS Basic Excl Extra (Annual)$-4.36

P/FCF (TTM)35.65x

Receivables Turnover (TTM)6.40x

EV / Free Cash Flow (TTM)72.09x

Total Debt / Equity (Quarterly)6.58x

EPS Incl Extra (TTM)$-3.88

Receivables Turnover (Annual)8.44x

ROI (TTM)-56.90%

P/S Ratio (TTM)2.56x

Pretax Margin (5Y Avg)-14.59%

Revenue / Share (Annual)$11.96

Tangible BV / Share (Annual)$1.24

Forward P/E63.06x

Price vs S&P 500 (52W)-50.45%

Year-to-Date Return-2.40%

5-Day Price Return-1.64%

EPS Normalized (Annual)$-4.36

ROA (5Y Avg)-20.61%

Net Profit Margin (Annual)-36.43%

Month-to-Date Return20.01%

Cash Flow / Share (TTM)$-0.60

EBITD / Share (Annual)$1.16

Operating Margin (Annual)7.08%

LT Debt / Equity (Annual)7.74x

P/CF (TTM)33.04x

ROI (5Y Avg)-27.77%

LT Debt / Equity (Quarterly)6.58x

EPS Basic Excl Extra (TTM)$-3.88

P/TBV (Quarterly)30.53x

P/B Ratio (Annual)35.14x

Inventory Turnover (TTM)2.42x

Pretax Margin (TTM)0.15%

Book Value / Share (Annual)$0.66

Price vs S&P 500 (13W)-1.58%

Beta1.19x

P/FCF (Annual)97.70x

Revenue / Share (TTM)$9.38

ROE (TTM)-246.36%

52-Week Low$16.05

vGradeD

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.05est. -0.13

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

4.14

4.13

Industry Peers — Orthopedic & Prosthetic Devices(33)

Symbol	Value Score	Growth Score	Momentum Score	Price
SMTISanara MedTech Inc. Common Stock	D	C	C	$21.92
ISRGIntuitive Surgical Inc.	D	B	D	$412.26
EWEdwards Lifesciences Corp	D	C	C	$88.16
STESTERIS plc	C	B	D	$211.07
ZBHZimmer Biomet Holdings, Inc.	B	C	D	$82.94
ALGNAlign Technology Inc	C	C	C	$169.77
SNNSmith & Nephew plc	B	C	C	$29.48
MSAMine Safety Incorporated	C	C	C	$163.13
ESTAEstablishment Labs Holdings Inc.	F	A	B	$68.08
CDRECadre Holdings, Inc.	C	C	D	$30.62
ENOVEnovis Corporation	B	D	D	$21.70

About

Sanara MedTech develops medical technologies for wound and skincare management across acute and post-acute care settings. Its portfolio includes CellerateRX for surgical wounds and BIAKOS for chronic wound care, addressing a substantial market opportunity. The company's comprehensive product offerings target improved clinical outcomes and reduced healthcare costs.